Literature DB >> 17997466

Comparative transforming potential of different human papillomaviruses associated with non-melanoma skin cancer.

Paola Massimi1, Miranda Thomas, Veronique Bouvard, Irene Ruberto, M Saveria Campo, Massimo Tommasino, Lawrence Banks.   

Abstract

It is well established that high-risk human papillomaviruses (HPVs) that infect mucosal epithelia are the causative agents of cervical cancer. In contrast, the association of cutaneo-tropic HPV types with the development of non-melanoma skin cancer (NMSC) is less well defined. In this study, we have analysed the in vitro transforming potential of various cutaneous HPV types. Using oncogene cooperation assays with activated ras, we have shown that diverse cutaneous types, including 12, 14, 15, 24, 36 and 49, have significant transforming potential. Interestingly, most of this activity appears to be encoded by the E6 gene product. In contrast, the common HPV-10 exhibits no significant transforming potential in these assays. This difference may be a reflection of different patterns of cellular localization, with transforming E6s being nuclear and non-transforming being cytoplasmic. These results provide molecular support for a role of these viruses in the development of certain human malignancies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17997466     DOI: 10.1016/j.virol.2007.10.015

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

Review 1.  Beta genus papillomaviruses and skin cancer.

Authors:  Peter M Howley; Herbert J Pfister
Journal:  Virology       Date:  2015-02-24       Impact factor: 3.616

2.  Genus beta human papillomavirus E6 proteins vary in their effects on the transactivation of p53 target genes.

Authors:  Elizabeth A White; Johanna Walther; Hassan Javanbakht; Peter M Howley
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

3.  NF-kappaB protects human papillomavirus type 38 E6/E7-immortalized human keratinocytes against tumor necrosis factor alpha and UV-mediated apoptosis.

Authors:  Ishraq Hussain; Ikbal Fathallah; Rosita Accardi; Jiping Yue; Djamel Saidj; Ruchi Shukla; Uzma Hasan; Tarik Gheit; Yamei Niu; Massimo Tommasino; Bakary S Sylla
Journal:  J Virol       Date:  2011-06-29       Impact factor: 5.103

4.  Potential risk factors for cutaneous squamous cell carcinoma include oral contraceptives: results of a nested case-control study.

Authors:  Maryam M Asgari; Jimmy T Efird; E Margaret Warton; Gary D Friedman
Journal:  Int J Environ Res Public Health       Date:  2010-02-03       Impact factor: 3.390

Review 5.  The papillomavirus E7 proteins.

Authors:  Ann Roman; Karl Munger
Journal:  Virology       Date:  2013-05-31       Impact factor: 3.616

6.  Differential regulation of cutaneous oncoprotein HPVE6 by wtp53, mutant p53R248W and ΔNp63α is HPV type dependent.

Authors:  Jian-Wei Fei; Ethel-Michele de Villiers
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

7.  Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2.

Authors:  Dorothea Muschik; Ilona Braspenning-Wesch; Eggert Stockfleth; Frank Rösl; Thomas G Hofmann; Ingo Nindl
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

8.  A Decade of Global mRNA and miRNA Profiling of HPV-Positive Cell Lines and Clinical Specimens.

Authors:  Bogumil Kaczkowski; Marya Morevati; Maria Rossing; Finn Cilius; Bodil Norrild
Journal:  Open Virol J       Date:  2012-12-28

9.  Immunologic Control of Mus musculus Papillomavirus Type 1.

Authors:  Joshua W Wang; Rosie Jiang; Shiwen Peng; Yung-Nien Chang; Chien-Fu Hung; Richard B S Roden
Journal:  PLoS Pathog       Date:  2015-10-23       Impact factor: 6.823

10.  Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection.

Authors:  Rosie T Jiang; Joshua W Wang; Shiwen Peng; Tsui-Chin Huang; Chenguang Wang; Fabiana Cannella; Yung-Nien Chang; Raphael P Viscidi; Simon R A Best; Chien-Fu Hung; Richard B S Roden
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.